Farmas USA

Futuros en verde, probable sesion de rebotes hoy y el VIX a la baja 

Acad

Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis

http://news.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-newsArticle&ID=2366704

Fuera antibióticos, MLNT y AKAO

TEVA

Orexo gana la revocación de la resolución de la patente relacionada con la droga opioide
10 de septiembre de 2018, 11:23:00 a.m. EDT por Reuters

Reuters

10 de septiembre (Reuters) - Un tribunal de apelaciones de los EE. UU. Dijo el lunes que la compañía farmacéutica sueca Orexo AB podría demandar que una unidad de Teva Pharmaceutical Industries Ltd infringió una patente relacionada con Zubsolv, un medicamento para tratar la dependencia de opiáceos.

Revocación de un fallo del tribunal inferior, el Tribunal de Apelaciones del Circuito Federal de los EE. UU. Dictaminó 3-0 que la unidad Actavis Elizabeth de Teva no pudo establecer mediante pruebas claras y convincentes que las reclamaciones de patentes de Orexo fueran inválidas porque eran "obvias".

El precio de las acciones de Orexo subió más del 30 por ciento luego de la decisión.

https://www.nasdaq.com/article/orexo-wins-reversal-of-patent-ruling-related-to-opioid-drug-20180910-00734

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

https://seekingalpha.com/pr/17265595-advaxis-reports-fiscal-2018-third-quarter-business-highlights-financial-results

Financial Results for Third Quarter Fiscal Year 2018

The net loss for the third quarter ended July 31, 2018 was $14.0 million or $0.27 per share. This compares with a net loss for the third quarter of fiscal year 2017 of $32.6 million or $0.80 per share. The $18.6 million reduction in the net loss compared to prior year was primarily a result of the significant reduction in spending in research, development and administrative areas.

Research and development expenses for the third quarter of fiscal year 2018 were $10.8 million, compared with $17.8 million for the third quarter of fiscal year 2017. The decrease is primarily attributable to a decrease in laboratory costs, drug manufacturing process validation and drug stability studies supporting the MAA, which we withdrew in July 2018.

General and administrative expenses for the third quarter of fiscal year 2018 were $4.5 million, compared with $18.0 million for the third quarter of fiscal year 2017. The decrease is primarily attributable to a decrease in stock-based compensation of approximately $11.4 million related to the resignation of the Company’s Chief Financial Officer and Chief Executive Officer in April 2018 and July 2017, respectively, two Board members who did not seek re-election in March 2018, a reduction in headcount and the elimination of stock-based compensation paid to consultants.

Balance Sheet Highlights

As of July 31, 2018, the Company had approximately $40.4 million in cash, restricted cash and cash equivalents on its balance sheet. The Company is anticipating closing on an underwritten public offering of its common stock and warrants on or around September 11, 2018 which is expected to result in gross proceeds of approximately $20 million to the Company

ADXS

AMRN y TGTX ... News de fase 3 este mes, no? Vaya animacion que gastan ...

KERX, diria que carne de corto en breve, nuevos minimos anuales en ciernes. Yo, como siempre, me espero al giro del estocastico despues de haber bajado de 20.

NVAX, a ver si esta consolidando antes del siguiente brinco a 1.7 ... Ya veremos ...

CELG mierda vela la de ayer, las aguanto por el momento, depende de lo que haga hoy

HZNP esta haciendo figura alcista, triangulo ascendente por lo que puedo apreciar

Pregunta sobre Interactive Brokers

No paran de mandarme notificaciones de "Aviso de incumplimiento de margen"

Yo no voy apalancado en nada, ni largo ni corto. Tengo unas acciones de NVAX y 1.300 $ de saldo, mas que suficiente para pagar las comisiones al dar al boton de vender cuando llegue el momento.

Entonces para que me envian ese mensaje? Hay alguna norma que vosotros sepais que obligue a tener una cantidad minima siempre en efectivo en la cuenta o que?